Thursday, December 02, 2021 7:25:53 PM
On August 31, 2021, the board of directors, by consent entered a Stock Purchase agreement with Vyome Therapeutics,
Inc., to sell to Vyome Therapeutics, Inc., 986,919 of the 996,919 of the company’s A-1 preferred shares. On the date of
closing, Vyome Therapeutics, Inc., purchased 996,919 shares of Livechain, Inc.’s, A-1 proffered stock, assuming
70.08% of the companies issued and outstanding shares. At the time of transfer, Venkat Nelabhotla, Chief Executive
Officer and Director of Vyome Therapeutics, Inc., also became Chief Executive Officer and Director of Livechain, Inc.
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM